TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-reported number of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Electrocardiogram results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infra-slow frequency power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Proportion of Viral Load Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: daily resting ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Copeptin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immunohistochemistry surrogate of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Machine learning algorithm performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rectal dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for culdocentesis or paracentesis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative nausea scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from baseline of probing pocket depth (PPD in mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of bone fill at re-entry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure on assigned NRS mode within 72 hours post-initial extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of All-cause Death, All Stroke and Aortic Insufficiency (AI) ≥ Moderate
Endpoint domain: Mortality/survival
Primary endpoint: Abstinence Duration
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Abstinence rate (%)
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Pain after shoulder surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wellbeing after shoulder surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum level of osteopontin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Time 72 hours (AUC72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tacrolimus exposure parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the dermal concentration versus time curve for lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the dermal concentration versus time curve for prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal dermal concentration of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal dermal concentration of prilocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of a major adverse cardiovascular event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Day-90 mortality
Endpoint domain: Mortality/survival
Primary endpoint: Radiographic Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Multidimensional Quality of Life Scale cancer MQOLS-CA
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thymidylate synthase expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: red blood cell transfusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent adherence to anti-epileptic drug schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24h (Area under the plasma concentration-time from 0 to 24 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibin-B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anti-Mullerian hormone (AMH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum tolerated dose of E7974
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of upper respiratory infections
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic and compartmental pharmacokinetics of dapivirine gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Side Effects of Oral Contraceptives
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Above the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Neisseria Meningitidis Using Baby Rabbit Complement (rSBA-MenC) Antibody Titers Above the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-perceived health status scale (36-Item Short Form Survey - SF36)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Colony Forming Units Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: DNA concentration in extracellular environment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time for the disappearance of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Montgomery Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: presence of strabismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: presence of nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: reduced acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: significant refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Gene expression in peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Type of facial asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Prematurely Discontinuing Due to a Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Skin colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: time to clinical recovery regarding infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: time to clinical recovery regarding pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to clinical recovery regarding kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of sensing (time to detection) in VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Triglyceride Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Positive Blood Culture for L. Reuteri
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Daily Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time CGM values in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PK parameters of probe drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (ORR) in CNS -brain metastasis cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival - Leptomeningeal with or without brain metastasis cohort
Endpoint domain: Mortality/survival
Primary endpoint: blood sugar control-fasting blood sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quality of life measured by the World Health Organization Quality of Life-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: blood sugar control-HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prescribed Post-discharge Opioids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Net change of Patient Perception of Bladder Condition (PPBC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Global Response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC (0 to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Closure Rate of Diabetic Foot Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal CD4+ t-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety as measured by the number of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects who achieve normalization of IGF-I SDS response during the first dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of subjects who achieve a mean IGF-I SDS within the defined target range after each dose titration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in QIDS-SR
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immediate reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD symptoms rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: virological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of consultations requiring medical advice
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Tolerated Dose (MTD) of MEK162
Endpoint domain: Adverse events/effects
Primary endpoint: Inter-rater reliability of the CIBA Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent validity of the CIBA Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Quit Rate at End-of-Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of Depo-Eligard®
Endpoint domain: Adverse events/effects
Primary endpoint: prolonged-remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: partial-remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DAS28-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean infant postprandial C peptide to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Documenting AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Determining the MTD of BI-1206
Endpoint domain: Adverse events/effects
Primary endpoint: Determine the recommended dose of BI-1206
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with suspected lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to first asthma relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in Moderate to Vigorous Physical Activity (MVPA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: extended Glasgow Outcome Scale (GOSe)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pressure in upper and lower esophageal sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Achieving 100% Improvement in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gamma camera-based whole-body 99mTc-1-thio-D-glucose uptake value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPECT-based 99mTc-1-thio-D-glucose value in tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor-to-background ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completely Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Daily Physical Activity (Counts Per Minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a More Than (>)1 Grams Per Deciliter (g/dL) Increase in Hemoglobin (Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Mean Overnight Oxygen Saturation (SpO2 Percentage [%])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: State Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absolute Change in Lung Clearance Index 2.5 (LCI2.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary (and -assisted) patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Score of Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Score of Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mobility Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gait measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Intestinal Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With IBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Receive Rapid HIV Treatment Initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Poor Mobilizers successfully collected in one day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of clinical and biological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: DAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive development of children
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Psychomotor development of children
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to onset of influenza/ARVI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of subclinical coronary artery atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of subclinical atherosclerosis in carotid and femoral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with mean IGF-1 levels ≤1xULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean atrial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventilatory metabolic response during the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of grade 2 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive impact assessed by memory test (SOC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of pulse-oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis and severity of OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of lab-based emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PADUA nephrometry score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of GDF15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication of diabetes
Endpoint domain: Adverse events/effects
Primary endpoint: Level of glycated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of fasting blood sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Breastfeeding Their Infants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of new asymptomatic cerebral embolic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: In vitro growth of Staph Aureus and Escherichia coli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: breast tissue limonene level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Self-reported Anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-reported Depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-reported Alcohol Abuse Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coagulation profile (prothrombin concentration and INR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Potassium serum ions level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Pelvic floor contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall Response of Success at the End of Intravenous Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive for SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Tic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Adjudicated Cardiovascular Events
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With an Adverse Event (AE) Leading to Death
Endpoint domain: Adverse events/effects
Primary endpoint: modified Rankin score 0-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Isofurans/Isoprostanes Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean Hysterotomy Myometrial Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean Hysterotomy Site Myometrial Percentage of Thinning at the Niche
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With/Without Dehiscence (>80% Thinning of the Myometrium) at the Niche
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary markers of renal tubular injury and interstitial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cosmetic Appearance Preference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life